Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

Cytotherapy

Volumn 19, Issue 4, 2017, Pages 500-513

  Kongsted, Per ^a   Borch, Troels Holz ^a   Ellebaek, Eva ^a   Iversen, Trine Zeeberg ^a   Andersen, Rikke ^a   Met, Özcan ^a   Hansen, Morten ^a   Lindberg, Henriette ^a   Sengeløv, Lisa ^a   Svane, Inge Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chemotherapy; dendritic cells; immunotherapy; mCRPC; prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; DENDRITIC CELL VACCINE; DOCETAXEL; ENZALUTAMIDE; MESSENGER RNA; OPIATE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; CANCER VACCINE; TAXOID;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SPECIFIC SURVIVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EX VIVO STUDY; FEBRILE NEUTROPENIA; HUMAN; HUMAN CELL; LEUKAPHERESIS; LOW DRUG DOSE; MALE; MIDDLE AGED; MONOCYTE; MONOTHERAPY; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; MYELOID-DERIVED SUPPRESSOR CELL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SPINAL CORD COMPRESSION; SURVIVAL TIME; TUMOR IMMUNITY; VERY ELDERLY; ADOPTIVE IMMUNOTHERAPY; AUTOTRANSPLANTATION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TRANSPLANTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 85012914647     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2017.01.007     Document Type: Article

References (42)

1. [1] Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Michael Glode, L., Bilhartz, D.L., Wyand, M., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28 (2010), 1099–1105.
2. [2] Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 (2010), 411–422.
3. [3] Waeckerle-Men, Y., Allmen, E.U., Fopp, M., von Moos, R., Böhme, C., Schmid, H.P., et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55 (2006), 1524–1533.
4. [4] Reyes, D., Salazar, L., Espinoza, E., Pereda, C., Castellón, E., Valdevenito, R., et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 109 (2013), 1488–1497.
5. [5] Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linné, C., Richter, K., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase i clinical trial. Prostate 66 (2006), 811–821.
6. [6] Lubaroff, D.M., Konety, B.R., Link, B., Gerstbrein, J., Madsen, T., Shannon, M., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 15 (2009), 7375–7380.
7. [7] Miller, A.M., Pisa, P., Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 56 (2007), 81–87.
8. [8] Flammiger, A., Weisbach, L., Huland, H., Tennstedt, P., Simon, R., Minner, S., et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 49 (2013), 1273–1279.
9. [9] Idorn, M., Køllgaard, T., Kongsted, P., Sengeløv, L., Thor Straten, P., Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63 (2014), 1177–1187.
10. [10] Tada, K., Kitano, S., Shoji, H., Nishimura, T., Shimada, Y., Nagashima, K., et al. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunol Res 4 (2016), 592–599.
11. [11] Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-Bevacizumab drug treatment regimen. Cancer Res 76 (2016), 5241–5252.
12. [12] Fitzpatrick, J.M., De Wit, R., Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 65 (2014), 1198–1204.
13. [13] Hodge, J.W., Garnett, C.T., Farsaci, B., Palena, C., Tsang, K.Y., Ferrone, S., et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 133 (2013), 624–636.
14. [14] Garnett, C.T., Schlom, J., Hodge, J.W., Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 14 (2008), 3536–3544.
15. [15] Kodumudi, K.N., Woan, K., Gilvary, D.L., Sahakian, E., Wei, S., Djeu, J.Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16 (2010), 4583–4594.
16. [16] Su, Z., Dannull, J., Yang, B.K., Dahm, P., Coleman, D., Yancey, D., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174 (2005), 3798–3807.
17. [17] Scher, H.I., Halabi, S., Tannock, I., Morris, M., Sternberg, C.N., Carducci, M.A., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
18. [18] Borch, T.H., Engell-Noerregaard, L., Iversen, T.Z., Ellebaek, E., Met, Ö., Hansen, M., et al. mRNA transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology, 5, 2016, e1207842.
19. [19] Miyara, M., Chader, D., Sage, E., Sugiyama, D., Nishikawa, H., Bouvry, D., et al. Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc Natl Acad Sci USA 112 (2015), 7225–7230.
20. [20] Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Löwer, M., et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 59 (2010), 1489–1501.
21. [21] Halabi, S., Lin, C.-Y., Kelly, W.K., Fizazi, K.S., Moul, J.W., Kaplan, E.B., et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32 (2014), 1–9.
22. [22] Figdor, C.G., de Vries, I.J.M., Lesterhuis, W.J., Melief, C.J.M., Dendritic cell immunotherapy: mapping the way. Nat Med 10 (2004), 475–480.
23. [23] Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110 (2013), 17945–17950.
24. [24] Sheikh, N.A., Petrylak, D., Kantoff, P.W., Dela Rosa, C., Stewart, F.P., Kuan, L.Y., et al. Sipuleucel-T immune parameters correlate with survival: an analysis if the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62 (2013), 137–147.
25. [25] Fakih, M., Johnson, C.S., Trump, D.L., Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60 (2002), 553–561.
26. [26] Small, E.J., Lance, R.S., Gardner, T.A., Karsh, L.I., Fong, L., McCoy, C., et al. A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res 21 (2015), 3862–3869.
27. [27] Harrop, R., Chu, F., Gabrail, N., Srinivas, S., Blount, D., Ferrari, A., Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother 62 (2013), 1511–1520.
28. [28] Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6 (2015), 18192–18205.
29. [29] Arlen, P.M., Gulley, J.L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12 (2006), 1260–1269.
30. [30] Met, Ö., Eriksen, J., Svane, I.M., Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Mol Biotechnol 40 (2008), 151–160.
31. [31] Javorovic, M., Wilde, S., Zobywalski, A., Noessner, E., Lennerz, V., Wölfel, T., et al. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J Immunother 31 (2008), 52–62.
32. [32] Wieckowski, E., Chatta, G.S., Mailliard, R.M., Gooding, W., Palucka, K., Banchereau, J., et al. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8+ T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate 71 (2011), 125–133.
33. [33] Hansen, M., Hjortø, G.M., Donia, M., Met, Ö., Larsen, N.B., Andersen, M.H., et al. Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine 31 (2013), 639–646.
34. [34] Muthuswamy, R., Mueller-Berghaus, J., Haberkorn, U., Reinhart, T.A., Schadendorf, D., Kalinski, P., PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116 (2010), 1454–1459.
35. [35] Montero, A.J., Diaz-Montero, C.M., Kyriakopoulos, C.E., Bronte, V., Mandruzzato, S., Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35 (2012), 107–115.
36. [36] Roselli, M., Cereda, V., di Bari, M.G., Formica, V., Spila, A., Jochems, C., et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology, 2, 2013, e27025.
37. [37] Vergati, M., Cereda, V., Madan, R.A., Gulley, J.L., Huen, N.Y., Rogers, C.J., et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 60 (2011), 197–206.
38. [38] Ellebaek, E., Engell-Noerregaard, L., Iversen, T.Z., Froesig, T.M., Munir, S., Hadrup, S.R., et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 61 (2012), 1791–1804.
39. [39] Von Bergwelt-Baildon, M.S., Popov, A., Saric, T., Chemnitz, J., Classen, S., Stoffel, M.S., et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108 (2006), 228–237.
40. [40] Hannani, D., Vétizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25 (2015), 208–224.
41. [41] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
42. [42] Graff, J.N., Alumkal, J.J., Drake, C.G., Thomas, G.V., Redmond, W.L., Farhad, M., et al. First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC). Ann Oncol, 27(Suppl. 6), 2016 abstract 719O.